Mercy., page-22

I'm a bit cautious on Sanofi. They seem to be slow adopters compared to Amgen and Medimmune. The break up of our revenue stands testimony to that, most of our revenue comes from two customers with a few hundred thousand from the third (I'm thinking that being Sanofi). I'm actually hesitant now in believing the auto-injector for Duplipumab is a WI... just seems a bit too early for me... if it was the other two customers, for sure....